Anti-microbial testing encompasses a suite of standardized experimental protocols designed to quantify the ability of substances—including natural extracts, synthetic compounds, advanced materials, and formulated products—to inhibit, inactivate, or eliminate microorganisms such as bacteria, fungi, viruses, and mycoplasmas. These tests are foundational to research and development (R&D) in fields ranging from pharmaceutical discovery to advanced materials science, providing quantitative and qualitative data on the efficacy of test agents against target microbes. Core metrics derived from such testing include Minimum Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC), zone of inhibition diameter, and time-kill kinetics, all of which serve as critical benchmarks for evaluating the performance of anti-microbial candidates in R&D pipelines.
The scientific rigor of anti-microbial testing is anchored in well-defined quantitative metrics that enable objective comparison of test agents. MIC, the lowest concentration of a substance that inhibits visible microbial growth, is the most widely used foundational metric, typically determined via broth dilution assays in 96-well microplates and measured turbidimetrically using spectrophotometers. For example, in screening plant-derived extracts for antibacterial activity, an MIC value of 128 μg/mL against Staphylococcus aureus (ATCC 25923) indicates that concentrations below this threshold fail to suppress bacterial proliferation. Complementary to MIC, MBC quantifies the lowest concentration required to kill ≥99.9% of the initial microbial inoculum, distinguishing bacteriostatic (growth-inhibiting) from bactericidal (lethal) effects. Time-kill kinetics further refine this understanding by tracking microbial viability at predefined intervals (e.g., 0, 2, 4, 8, 24 hours) following exposure to the test agent, revealing the rate of microbial elimination and potential for resistance emergence. For instance, a novel peptide with an MBC of 64 μg/mL against Escherichia coli and a 3-log reduction in colony-forming units (CFU) within 4 hours demonstrates rapid bactericidal activity, a desirable trait for R&D candidates targeting acute infections.
The reliability of anti-microbial testing results is contingent on strict control of experimental variables, as deviations can lead to erroneous conclusions about a test agent's efficacy. Microbial inoculum size is a primary variable; standardized concentrations (typically 10⁵–10⁶ CFU/mL) ensure consistent exposure to the test substance, as larger populations require longer exposure times for complete elimination. Culture medium composition is equally critical: Mueller-Hinton broth, for example, is the gold standard for antibacterial susceptibility testing due to its low cation content, which minimizes interference with antimicrobial activity, while Sabouraud dextrose agar is preferred for fungal testing due to its acidic pH (5.6) that inhibits bacterial overgrowth. Environmental factors, including incubation temperature (35–37°C for most bacteria, 25–30°C for fungi) and atmospheric conditions (aerobic, anaerobic, or microaerophilic), must be tailored to the metabolic requirements of the target microbe. Organic matter, such as serum or protein, can also diminish antimicrobial activity by binding to test agents, a factor particularly relevant for R&D focused on materials intended for biological environments. For example, testing a wound dressing material in the presence of 5% human serum more accurately simulates in vivo conditions than testing in a protein-free medium, providing more translatable data for subsequent development stages.
Advanced anti-microbial testing goes beyond efficacy quantification to elucidate the mechanisms by which test agents interact with microbial cells, a key requirement for optimizing R&D candidates. Phenotypic assays, such as membrane integrity studies using fluorescent dyes (e.g., propidium iodide, which penetrates damaged cell membranes), can identify whether an agent acts by disrupting microbial membranes—a common mechanism of natural antimicrobials like essential oils. Metabolic inhibition can be assessed via resazurin assays, where the reduction of a blue dye to a pink fluorescent product indicates active microbial metabolism; a lack of fluorescence in the presence of the test agent confirms metabolic suppression. For novel materials like anti-microbial coatings, biofilm inhibition assays are critical, as biofilms—structured microbial communities encased in extracellular polymeric substances—are often more resistant to antimicrobials than planktonic cells. Testing protocols that quantify biofilm biomass via crystal violet staining or measure metabolic activity within biofilms provide insights into a material's ability to prevent biofilm formation, a key performance criterion for applications in medical devices and industrial surfaces.
CD BioSustainable's anti-microbial testing services are exclusively tailored to support R&D initiatives, providing comprehensive, science-driven assessments of novel compounds, materials, and formulations across academic and industrial research pipelines. Our services are designed to address the unique needs of researchers developing anti-microbial agents for advanced materials, pharmaceutical discovery, agricultural biocides, and environmental remediation, with a focus on delivering actionable data that accelerates candidate optimization and de-risking.
Our high-throughput screening (HTS) services enable rapid antimicrobial activity evaluation of large compound libraries (up to 10,000 samples per run) against panels of reference and clinically relevant microbial strains. Leveraging automated liquid handling systems and 384-well microplate formats, we quantify Minimum Inhibitory Concentration (MIC) values and inhibition rates via absorbance or fluorescence detection, shortening the time to identify hit compounds. Customizable strain panels cover gram-positive bacteria (S. aureus, Streptococcus pneumoniae), gram-negative bacteria (E. coli, Klebsiella pneumoniae), fungi (C. albicans, Aspergillus niger), and viruses (e.g., influenza A, lentiviruses) for diverse research needs.
Our service is tailored for researchers developing antimicrobial materials (coatings, textiles, polymers, nanomaterials), assessing the ability of solid-phase materials to inhibit or kill surface microbes. For non-porous materials like plastics, microbial suspensions are inoculated onto samples, and viable microbe counts are measured after 24 hours of contact. For porous materials such as textiles, modified testing protocols under dynamic contact conditions are applied. Additional options include biofilm inhibition assays to evaluate material performance against sessile microbial communities.
Designed for lead optimization, Our services reveal the mode of action of promising antimicrobial candidates to guide structural modification and formulation development. Time-kill kinetic assays generate viability curves to distinguish bactericidal and bacteriostatic effects and determine microbial elimination rates. Membrane integrity assays (flow cytometry) and metabolic inhibition assays (resazurin-based detection) further clarify whether candidates act by disrupting cell membranes, inhibiting protein synthesis, or interfering with nucleic acid replication. These data are critical for predicting cross-resistance potential and optimizing efficacy for target applications.
Traditional phenotypic methods remain the backbone of anti-microbial testing, offering robust, cost-effective solutions for initial R&D screening. The disk diffusion (Kirby-Bauer) method involves placing filter paper disks impregnated with the test agent on an agar plate inoculated with a confluent microbial lawn; the diameter of the clear zone of inhibition surrounding each disk is measured to assess anti-microbial activity. This method is particularly useful for qualitative screening of diffusible compounds, such as plant extracts or small molecules, and is standardized for reference strains via CLSI and EUCAST guidelines. Broth microdilution, the gold standard for MIC determination, involves preparing serial two-fold dilutions of the test agent in a liquid medium (e.g., Mueller-Hinton broth) in 96-well plates, followed by inoculation with the target microbe and incubation for 16–24 hours. Growth is assessed via spectrophotometry (absorbance at 600 nm) or visually, with the MIC defined as the lowest concentration with no visible growth. The agar dilution method, a variation of broth dilution, embeds the test agent in agar medium and is used for testing slow-growing microbes or compounds with low aqueous solubility.
Advanced technologies have revolutionized anti-microbial testing by reducing assay time and enhancing sensitivity, critical for accelerating R&D timelines. Flow cytometry enables rapid quantification of viable microbial cells by staining with fluorescent dyes that distinguish live (intact membranes) from dead (damaged membranes) cells, providing results in 1–2 hours compared to 24–48 hours for traditional methods. This technology is particularly valuable for time-kill kinetic studies, where real-time viability data are required. Microfluidic chip technology, utilizing microscale channels to handle picoliter to microliter volumes, offers high-throughput, low-cost testing with precise control of experimental conditions. CD BioSustainable employs droplet-based microfluidic systems for high-throughput screening of compound libraries, enabling parallel testing of hundreds of concentrations and microbial strains with minimal reagent and sample consumption. Bioluminescent assays, which measure ATP levels as an indicator of microbial viability, provide quantitative results in 30–60 minutes and are used for rapid assessment of anti-microbial efficacy in high-throughput formats.
Mechanistic characterization relies on advanced analytical technologies to elucidate the interaction between the test agent and microbial cells. Flow cytometry, coupled with fluorescently labeled antibodies or nucleic acid probes, enables targeted analysis of cell membrane integrity, protein synthesis, and DNA replication inhibition. For example, staining with DiOC6 (a membrane potential-sensitive dye) can identify agents that disrupt microbial proton gradients, a common mechanism of action for antibiotics like polymyxins. Raman spectroscopy, a non-destructive vibrational spectroscopy technique, provides chemical fingerprints of microbial cells exposed to the test agent, revealing changes in lipid, protein, and nucleic acid composition that indicate specific modes of action. MALDI-TOF mass spectrometry (MS) further enables identification of microbial strains and detection of metabolite changes induced by the test agent, supporting the characterization of resistance mechanisms and cross-resistance potential. These technologies provide deep mechanistic insights that guide rational design of anti-microbial candidates in advanced R&D stages.
If you are interested in our services and products, please contact us for more information.
For Research or Industrial Raw Materials, Not For Personal Medical Use!
|
There is no product in your cart. |
CD BioSustainable is a reputable and specialized company in the field of advanced materials, we provide high-quality products, customizable services, and total solutions to meet clients' requirements.
Enter your E-mail and receive the latest news from us.
Copyright © CD BioSustainable. All rights reserved.